BOTHELL, Wash., Jan. 18, 2011 /PRNewswire/ — BioLife Solutions,
Inc. (OTC Bulletin Board:
BLFS) announced today that it has significantly increased its
financial support for several key organizations in the regenerative
medicine industry. The worldwide regenerative medicine market
is comprised of nearly 1,000 commercial companies and hospitals,
which are developing cell and tissue-based products and therapies
to treat cancer, heart disease, diabetes, neurologic disorders,
movement disorders, and many other afflictions.
(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)
Chairman and CEO Mike Rice explained the Company’s interest to
support the regenerative medicine industry by stating, “The
regenerative medicine industry is a strategic market segment for
BioLife, where the critical value of our novel, clinical grade
biopreservation media products continues to be recognized by a
growing number of commercial companies and hospital-based
transfusion centers. We understand that broad-based,
worldwide adoption of any novel, enabling technologies such as our
HypoThermosol® and CryoStor® products must be driven by
scientific proof and a thorough vetting of the supplier’s
operations and quality systems, and we’re actively engaged in these
organizations by holding committee membership positions, presenting
at scientific conferences, and contributing to the creation of best
practices documents and standards that can improve the quality of
the manufacturing, transportation, infusion, and clinical efficacy
of new cell and tissue-based regenerative medicine products and
therapies.”
Most recently, BioLife joined the Alliance for Regenerative
Medicine (ARM) as a corporate member for 2011. ARM is a
Washington, DC-based non-profit organization whose mission is to
ed
‘/>”/>
